Suvorexant 20 mg

DRUG9 trials

Conditions

Alcohol Use DisorderAlcohol Use Disorder (AUD)Alzheimer DiseaseCortisol; HypersecretionCravingDelirium in Old AgeInsomniaNicotine Dependence

Phase 1

Targeting Orexin to Treat Nicotine Dependence

Active, not recruitingNCT03999099

Mclean HospitalNicotine Dependence

Start: 2019-09-26End: 2026-12-31Target: 45Updated: 2026-07-14

Phase 2

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

CompletedNCT03412591

Milton S. Hershey Medical CenterCortisol; Hypersecretion, Craving, Sleep Disturbance

Start: 2019-07-01End: 2023-01-07Updated: 2024-02-13

Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence

TerminatedNCT03897062

The Florey Institute of Neuroscience and Mental HealthAlcohol Use Disorder, Insomnia

Start: 2019-08-26End: 2022-07-31Updated: 2023-02-15

Medication Development in Alcoholism: Suvorexant Versus Placebo

CompletedNCT04229095

The Scripps Research InstituteAlcohol Use Disorder (AUD)

Start: 2021-11-17End: 2022-11-08Updated: 2023-04-26

Suvorexant to Reduce Symptoms of Nicotine Use

CompletedNCT04234997

The University of Texas Health Science Center, HoustonSmoking Cessation

Start: 2021-08-23End: 2024-08-22Updated: 2025-10-01

Sleep Trial to Prevent Alzheimer's Disease

RecruitingNCT04629547

University of MinnesotaAlzheimer Disease, Sleep

Start: 2022-05-25End: 2028-05-01Target: 120Updated: 2026-07-13

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

CompletedNCT05733286

Duke UniversityDelirium in Old Age

Start: 2023-06-28End: 2025-07-07Updated: 2026-01-15

Phase 4

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

CompletedNCT03312517

Henry Ford Health SystemInsomnia

Start: 2018-04-15End: 2018-10-25Updated: 2019-11-01

Suvorexant and Sleep/Delirium in ICU Patients

CompletedNCT04092894

Beth Israel Deaconess Medical CenterInsomnia, Postoperative Delirium, Sleep Fragmentation +1

Start: 2020-02-28End: 2025-07-01Updated: 2025-10-27

Related Papers

Effect of the orexin receptor antagonist, suvorexant, on sleep architecture in the early postoperative period following cardiac surgery: a randomized controlled trial

Critical Care2026-06-23

Protocol and design of the REPOSE study: a double-blinded, randomised, placebo-controlled trial to evaluate the efficacy of suvorexant to improve postoperative sleep and reduce delirium severity in older patients undergoing non-cardiac surgery

BMJ Open2025-03-012 citations

Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit

BMJ Open2020-07-019 citations

Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?

2019-09-016 citations